Kidney cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• HIF-1 0
• YAP 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

24 of 1,801 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finland· EU contribution €226,277· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €1,500,000· until Dec 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Italy· EU contribution €2,496,625· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, France· EU contribution €5,577,694· until Apr 2028· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €5,906,596· until Mar 2027· 7 countries

5 of 6 running projects, newest first. Listed amounts together: €19.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

  NCT05935748· NiKang Therapeutics, Inc.· Updated 12 Nov 2026

  “This study was terminated as a result of Sponsor portfolio reprioritization.”Registry text, quoted unchanged. Source

• Terminated

  Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery

  NCT07062952· Jinling Hospital, China· Updated 9 Nov 2026

  “The study was discontinued following a reassessment of the original protocol, which identified the need for substantial modifications to the study design and implementation. The original study was therefore considered unsuitable for continuation”Registry text, quoted unchanged. Source

• Terminated

  Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

  NCT06005818· University of Alabama at Birmingham· Updated 3 Nov 2026

  “Loss of funding”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Trial of ADI-270 in ccRCC

  NCT06480565· Adicet Therapeutics· Updated 27 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

  NCT07179770· NYU Langone Health· Updated 22 Oct 2026

  “PI Departure”Registry text, quoted unchanged. Source

• Terminated

  Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

  NCT03274258· M.D. Anderson Cancer Center· Updated 20 Oct 2026

  “The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Updated 20 Oct 2026

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”Registry text, quoted unchanged. Source

• Suspended

  Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

  NCT06049576· City of Hope Medical Center· Updated 8 Oct 2026

  “09/29/2026 DSMC: Opened in order to apply suspension.”Registry text, quoted unchanged. Source

• Suspended

  Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

  NCT03575611· M.D. Anderson Cancer Center· Updated 6 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Withdrawn

  RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

  NCT07218692· City of Hope Medical Center· Updated 1 Oct 2026

  “Study Abandoned withdrawn”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166· National Cancer Institute (NCI)· Source

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Source

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

  NCT05411081· National Cancer Institute (NCI)· Source

• Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  NCT04616560· National Cancer Institute (NCI)· Source

• Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

  NCT00033137· National Cancer Institute (NCI)· Source

• A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  NCT07227402· Merck Sharp & Dohme LLC· Source

• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

  NCT04071223· National Cancer Institute (NCI)· Source

• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Merck Sharp & Dohme LLC· Source

• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

  NCT00050752· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

  Oncologist, Oct 2026

• Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing.

  Mol Cancer Res, May 2026

• Improving the diagnosis of renal tumours of young people through integrated molecular analysis.

  J Cancer Res Clin Oncol, Apr 2026

• Germline duplication of MYCN predisposes to childhood embryonal tumours.

  EBioMedicine, Jan 2026

• Distinct genomic, microenvironmental, and nephron signatures in VHL kidney cysts and tumors.

  Sci Rep, Jan 2026

• Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.

  Nat Commun, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.